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Abstract
Optimal debulking followed by chemotherapy is the standard treatment of managing late-stage ovarian cancer, but
chemoresistance is still a major problem. In this study, we compared expression profiles of primary tumor tissue
from five long-term (>8 years) and five short-term (<2 years) ovarian cancer survivors and identified clusterin as
one of the genes that were significantly up-regulated in short-term survivors. We then evaluated the prognostic
significance of clusterin and its possible correlation with chemoresistance in ovarian cancer by immunohistostain-
ing of clusterin in 62 tumor samples from patients with stage III, high-grade serous ovarian cancer. After adjusting
for debulking status and age, Cox regression analyses showed that high levels of clusterin expression correlate with
poor survival (hazard ratio, 1.07; 95% confidence interval, 1.002–1.443; P = .04). We also investigated clusterin in
paclitaxel resistance by modulating the endogenous clusterin expression in ovarian cancer cells and treating the cells
with purified clusterin. Results indicate that high-clusterin–expressing ovarian cancer cells are more resistant to pac-
litaxel. Moreover, exposing ovarian cancer cells to exogenous clusterin increases cells’ resistance to paclitaxel. Fi-
nally, using size exclusion chromatography and fluorescently labeled paclitaxel, we demonstrated that clusterin binds
to paclitaxel. In summary, our findings suggest that high levels of clusterin expression increase paclitaxel resistance
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in ovarian cancer cells by physically binding to paclitaxel, which may prevent paclitaxel from interacting with micro-
tubules to induce apoptosis. Thus, clusterin is a potential therapeutic target for enhancing chemoresponsiveness in
patients with a high-level clusterin expression.
Neoplasia (2008) 10, 964–972
Introduction
Epithelial ovarian cancer, the most common human ovarian cancer
[1], is also the most lethal, partly because 75% of ovarian cancers are
detected as late-stage disease [2] and 25% of tumors do not respond
to standard chemotherapy. Nevertheless, after surgical debulking of
the tumor and standard chemotherapy, approximately 5% to 10%
patients experience 5-year progression-free survival and are therefore
considered long-term survivors [3]. Identifying new molecular ther-
apeutic targets for the treatment of the disease should improve these
outcomes, but to do so, we must first gain greater insight into the
pathogenesis of ovarian cancer, perhaps by better understanding
the molecular differences between tumors from short- and long-term
ovarian cancer survivors.
Transcription profiling, one increasingly standard approach to in-
vestigating global gene expression differences in cancer samples [4–
10], has already been used to identify many potential prognostic
biomarkers and therapeutic targets. In this study, our primary pur-
pose was to identify a list of genes that are significantly up-regulated
in short-term survivors by transcription profiling. It is hoped that
some of these genes might be potential therapeutic targets. Clusterin
was found to be one of the genes that are significantly up-regulated
in short-term survivors.
Although previous studies have established that high levels of clus-
terin expression correlate with the progression of various cancers,
such as cancer of the bladder [11], breast [12], and prostate [13],
and that clusterin may also be involved in chemoresistance in these
cancers [14–16], the correlation of high clusterin expression in
ovarian cancer cells with short-term survival and chemoresistance
in ovarian cancer patients has not been established. Therefore, in this
study, we sought to clarify the prognostic significance of clusterin in
ovarian cancer and explore its role in chemoresistance. By manipu-
lating clusterin expression and exposure in several ovarian cancer cell
lines and using size exclusion chromatography and fluorescently la-
beled paclitaxel, we found that clusterin increases the resistance of
ovarian cancer cells to paclitaxel by binding to it, both in vivo and
in vitro. Furthermore, immunohistochemical analyses of 62 indepen-
dent ovarian tumor samples from patients with stage III, high-grade
serous ovarian cancer showed that high levels of clusterin expression
correlate with poor overall survival rates.
Materials and Methods
Microarray Analysis
Affymetrix U133plus2 GeneChips (Santa Clara, CA) were used to
generate expression profiles of microdissected tumor cells from five
long-term (survival time, 95-192 months) and five short-term (sur-
vival time, 13-21 months) survivors with stage III, grade 3 serous
ovarian cancer as described previously (Figure 1) [17]. All patients
received an optimal debulking surgery and treatment with six cycles
of paclitaxel and cisplatin. Raw images (“.DAT” files) from an Affy-
metrix GeneChip scanner were processed with dChip software [18].
The raw signals of individual probes for all 10 arrays were normalized
against the chip with the median raw signal intensity, and normali-
zation was based on an “invariant set” of probes consisting of points
from nondifferentially expressed genes. After normalization, the
expression values of each gene in all the samples were computed
using a perfect match-only model and an outlier detection algorithm.
Normalized expression values from dChip analyses were used for a
two-class unpaired SAM analysis. Differentially expressed genes
Figure 1. Partial list of differentially expressed genes in tumors from
long- and short-term ovarian cancer survivors. The length of survival
for each patient is shown within a labeled bracket. Red, white, and
blue indicate a fold-change expression level above, at, and below
the mean expression of a gene across all samples, respectively.
Neoplasia Vol. 10, No. 9, 2008 Clusterin Confers Paclitaxel Resistance Park et al. 965
were identified by supervised analysis with Significance Analysis of
Microarrays (SAM) software [19], which yields results similar to
those obtained using Student’s t test but includes permutations to
calculate the false discovery rate, or a q value, for each gene. Each
q value represents the probability that a gene is falsely identified as
differentially expressed, with smaller q values indicating more signif-
icant differential expression levels.
Cell Lines and Tissue Samples
All 13 ovarian cancer cell lines (PEO4, CAOV3, OVCA420,
TOV21G, RMUG-S, RMUG-L, OVCA822, 0V2008, ES2, TOV112,
OVCA433, OVCA432, and SKOV3) were grown in a medium of
equal parts M199 and MCDB105 supplemented with 10% fetal
bovine serum as described previously [20]. All tumor specimens
from patients were collected and archived according to protocols
approved by the institutional review boards of the appropriate insti-
tutions that included an informed consent or a waiver. All the pa-
tients had stage III and grade III serous ovarian tumors and were
treated uniformly with paclitaxel/carboplatin first-line chemother-
apy regimen.
Immunohistochemistry
Five normal ovarian surface epithelial samples and 62 samples
from previously untreated stage III, high-grade primary papillary
serous carcinomas were immunostained using an avidin-biotin
method with an anti–clusterin α chain mouse monoclonal antibody
(5 μg/ml; Upstate Biotechnology, Lake Placid, NY), with clusterin
expression scored as described previously [21]. Cox regression and
Kaplan-Meier survival analyses were used to compare immunohisto-
chemical results with patient survival data. Statistical significance was
determined by using the log rank test with statistical software SPSS
version 15.0.
Western Blot Analysis
Cell lysates were prepared from the 13 ovarian cancer cell lines
[20] and subjected to Western blot analysis using an anti–clusterin
mouse monoclonal antibody (Upstate Biotechnology) and an anti–
β-actin monoclonal antibody for normalization of protein loading.
Immunoreactivity was detected using the ECL chemiluminescence
system (Amersham, Piscataway, NJ) and quantified using an imaging
densitometer (Model GS-670; Bio-Rad, Hercules, CA).
IC50 and Cell Proliferation Assay
Cells (1 × 104 per well) were seeded in a 96-well plate in 0.1 ml of
culture medium and allowed to grow overnight. The next day, the
medium was supplemented with either vehicle control or 10−9 to
10−4 M paclitaxel (Sigma, St. Louis, MO). The 50% inhibitory drug
concentration (IC50) was determined using the 2,3-bis(2-methoxy-4-
nitro-5-sulfophenyl)-2H -tetrazolium-5-carboxanilide (XTT) assay
(Roche Molecular Biochemicals, Indianapolis, IN) according to the
manufacturer’s instructions. The metabolism of XTTwas quantified
by measuring the absorbance at 450 nm, and the IC50 of paclitaxel
for each of the cell lines was estimated from the semilogarithmic
dose-response curves by linear interpolation.
DNA Fragmentation Assay for Apoptosis
Cells (1 × 104 per well) were seeded in a 96-well plate in 0.1 ml
of culture medium and allowed to grow overnight. The next day, cells
were treated with 10−7 M paclitaxel for 48 hours at 37°C in the pres-
ence or absence of clusterin. The amounts of cytoplasmic histone-
associated DNA fragments (mononucleosome and oligonucleosomes)
formed during apoptosis were measured using a cell death detection
ELISAPlus kit (Roche Molecular Biochemicals) according to the manu-
facturer’s instructions. Each assay was performed in quadruplicate, and
each experiment was repeated three times. The relative percentages of
DNA fragmentation were calculated as the ratios OD405 readings from
paclitaxel-treated to paclitaxel-untreated cells.
Generation of Stably Transfected Cells
Overexpressing Clusterin
SKOV3 cells were transfected with full-length clusterin cDNA
cloned into pcDNA3.1 expression vectors (pcDNA3.1/CLU) using
FuGENE 6 transfection reagent according to the manufacturer’s
protocol (Roche Molecular Biochemicals). Mock transfection was
performed the same way, using the vector pcDNA3.1. Stably trans-
fected clones were selected 36 hours later by adding G418 (Roche
Molecular Biochemicals) at 500 μg/ml. The stable clones were then
evaluated for the expression of clusterin and paclitaxel resistance.
In Vitro Small Interfering RNA–Mediated Gene Silencing
Clusterin small interfering RNA (siRNA) duplex, consisting of
nucleotides +85 to +96 (where the translation start site was defined
as +1; Dharmacon Research, Lafayette, CO), or luciferase GL2
Duplex (Dharmacon) at 0.2 nmol/ml was transfected into ovarian can-
cer cells expressing high levels of clusterin (PEO4, RMUG-S, and
TOV21G) using an oligofectamine reagent (Invitrogen, Carlsbad,
CA) as described by the manufacturer’s protocols (Life Technologies,
Inc., Gaithersburg, MD). Transfected cells were evaluated for clusterin
expression and sensitivity to paclitaxel.
Exogenous Clusterin Treatment
Clusterin was purified from human sera by immunoaffinity chro-
matography, using an anti–clusterin monoclonal antibody under
native conditions at 4°C as described previously [22]. Analysis of
clusterin purity by SDS-PAGE showed a major band (nonreduced)
at 75 to 80 kDa [22]. To further ensure the purity of the product,
we performed an additional purification step using ion-exchange
chromatography. The eluate from the immunoaffinity column was
dialyzed against 50 mM Tris buffer (pH 8.0), loaded onto a Q-
Sepharose FF column, and eluted with a linear NaCl gradient in the
same buffer. Clusterin-containing fractions (as judged by SDS-PAGE)
were then pooled and concentrated. SKOV3 cells (1 × 104 cells per
well) in 96-well plates were treated with 10−7 M paclitaxel in the pres-
ence of 0.5, 2.5, 5, and 7.5 and 15 μg/ml purified clusterin for 48 hours
at 37°C. Cells were then harvested for XTT and apoptosis assays.
In Vivo Short Hairpin RNA–Mediated Gene Silencing
Using a Lentiviral Expression System
A Lentiviral vector expressing short hairpin RNA (shRNA) tar-
geting clusterin was constructed using the BLOCK-iT Lentiviral
RNAi expression system (Invitrogen). DNA oligonucleotides en-
coding shRNA of clusterin (CLU) were designed using BLOCK-
iT RNAi designer (Invitrogen) and inserted downstream of the
human U6 pol III promoter and upstream of a pol III terminator
in pENTR/U6 vector (Invitrogen) and then into the vector pLenti-
GW/U6 as pLenti-GW/U6-CLUshRNA. Lentiviral particles were
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then generated from pLenti-GW/U6-CLUshRNA by transfecting
293 FT cell lines with the shRNA construct and helper plasmids.
To investigate the effects of decreased clusterin expression on
paclitaxel resistance in xenografted tumors, forty 6- to 8-week-old
female nude mice (SLC; Shizuoka, Japan) were evenly distributed for
generating xenograft mouse models using control cells (PEO4 trans-
duced with Lentiviral particles carrying shRNA for the LacZ gene)
or clusterin knockdown cells (PEO4 transduced with Lentiviral parti-
cles carrying shRNA for the CLU gene). After being transduced with
Lentiviral particles carrying shRNA for the LacZ or CLU gene over-
night, 5 × 105 paclitaxel-resistant PEO4 cells were used to inoculate
subcutaneously into the posterior neck region of each nude mouse.
When the xenografts grew to approximately 100 mm3, mice were in-
jected intraperitoneally with 0.2 mg/0.1 ml per 10 g of paclitaxel three
times per week for 3 to 4 weeks. Tumor volumes were measured twice
every week and calculated using the formula: length × width × depth ×
0.5236. The mice were euthanized at day 27, and the levels of clusterin
expression in xenografted tumors were determined by Western blot
analysis. Animals were housed in pathogen-free units in compliance
with institutional animal care and use committee regulations.
Effects of Clusterin on the Binding of Paclitaxel to
Microtubules in Ovarian Cancer Cells
PEO4 and SKOV3 cells were trypsinized, inoculated into cham-
bered coverglasses (Fisher Scientific, Pittsburgh, PA), and incubated
for 12 hours at 37°C. The cells were washed three times with 2%
BSA/PBS, 10−6 M Oregon Green (OG) 488–labeled paclitaxel
(paclitaxel-OG; Invitrogen) was added, and the cells were incubated
for 1 hour at 37°C in PEM buffer (50 mM PIPES, 2 mM EGTA,
2 mM MgCl2, pH 7.4), with or without 7.5 mg/ml purified clus-
terin. After incubation with the 10−6 mg/ml Hoechst 33258 penta-
hydrate (Molecular Probes, Eugene, OR) for 15 minutes at 37°C, the
cells were examined using a Leica DMIRE2 inverted fluorescence
microscope with appropriate filters.
Measurement of Paclitaxel-Clusterin Binding
Solutions of clusterin or control protein glutathione-S -transferase
(GST) at 5 mM, alone or in the presence of a 1:1 molar ratio of
paclitaxel-OG, phalloidin-OG, or OG in PEM were incubated for
1 hour at 37°C. Then, solutions were fractionated using size exclusion
chromatography with a Biosep SEC S4000 column (Phenomenex,
Sydney, Australia) and an AKTA FPLC system (GE Healthcare,
Sydney, Australia); the A280 of the eluate, as an indication of pro-
tein elution, was measured continuously. Collected fractions (200 ml
each) were transferred into the wells of black 96-well plates (Greiner,
Frickenhausen, Germany), and the fluorescence of paclitaxel-OG,
phalloidin-OG, and OG was measured using a Fluostar microplate
reader (BMG Labtech, Melbourne; excitation, 485 ± 5 nm; emis-
sion, 520 ± 5 nm). Other control proteins (superoxide dismutase
and hemoglobin) were also tested.
Results
Expression Profiling of Microdissected Tumors from
Short- and Long-term Survivors
Using SAM analysis to compare the expression profiles of tumors
from five short- and five long-term ovarian cancer survivors, we iden-
tified 77 probe sets with greater than threefold expression in short-
than in long-term survivors (Table W1; q < 15%). Two of these
probe sets encode clusterin that was up-regulated 3.8-fold more in
short- than in long-term survivors (Figure 1).
Clusterin Expression Correlates with Poor Survival
and Chemoresponse
To evaluate whether clusterin expression correlates with poor sur-
vival, clusterin immunostaining was performed on an independent
set of 62 ovarian cancer samples from patients with stage III, grade
3 serous ovarian cancers. After adjustment for optimal debulking and
age, Cox regression analyses showed that high clusterin expression
correlates with poor survival [hazard ratio (HR), 1.07; 95% confi-
dence interval (CI), 1.002–1.443; P = .04]. In addition, using me-
dian weight scores as cutoffs, Kaplan-Meier survival analyses showed
that patients with positive clusterin expression had significantly re-
duced survival times in both optimally and suboptimally debulked
Figure 2. Clusterin expression correlates with overall survival and
chemoresponse. (A) Kaplan-Meier survival curves for patients with
stage III, high-grade serous ovarian adenocarcinomas. Patients
who had tumors with positive clusterin expression (+) had signif-
icantly poorer prognoses than those who had negative clusterin
expression (−), whether their debulking was optimal (i.e., the larg-
est residual tumor was <2 cm) or suboptimal (i.e., the largest re-
sidual tumor was >2 cm). (B) Box-plot showing clusterin protein
expression in chemoresponders and nonresponders. The box is
bounded above and below by the 75th and 25th percentiles, and
the median is the line in the box. Whiskers are drawn to the nearest
value not beyond a standard span from the quartiles; points beyond
(outliers) are drawn individually, where the standard span is 1.5 ×
(interquartile range).
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cases (P = .001 and P = .0096, respectively; Figure 2A). Normal ovar-
ian surface epithelial cells had no immunostaining of clusterin. The
immunostaining intensities of clusterin (weight score) in the non-
responder group was significantly (P = .019) higher than those in
the responder group (Figure 2B).
Clusterin Expression Correlates with Paclitaxel Resistance
in Ovarian Cancer Cell Lines
To test whether high clusterin expression is associated with chemo-
resistance, we determined the level of clusterin protein expression
and paclitaxel IC50 values in 13 ovarian cancer cell lines. The Western
blot showed that four cell lines (PEO4, RMUG-S, OVCA822, and
TOV21G) had very high levels of clusterin expression (Figure 3A)
and that these cell lines were the most resistant to paclitaxel. A sig-
nificant correlation between clusterin expression and paclitaxel IC50
is illustrated in Figure 3B (Spearman’s test, R2 = 0.55, P = .004).
We have also determined the IC50 values for cisplatin, carboplatin,
topotecan, and doxorubicin for these cell lines; however, no significant
correlation was found.
Up-regulation of Clusterin Expression Increases Paclitaxel
Resistance of SKOV3 Cells
Paclitaxel-sensitive SKOV3 cells, which express low levels of clus-
terin, were stably transfected with a full-length human clusterin
cDNA construct or with the vector alone. Cells transfected with
the stable SKOV3/pcDNA3.1/CLU expressed high levels of clusterin
and were more resistant to paclitaxel than those transfected with the
vector control SKOV3/pcDNA3.1 (Figure 4, A and B; P < .05).
Exogenous Clusterin Enhances Paclitaxel Resistance
of SKOV3 Ovarian Cancer Cells
Because clusterin is a secreted protein, we evaluated the effects of
exogenous clusterin on paclitaxel resistance. In the presence of pac-
litaxel, the number of surviving SKOV3 cells increased with the
amount of exogenous clusterin (Figure 5; P < .05). As a control,
we also tested the effect of clusterin alone on cell proliferation. There
is no significant effect on cell proliferation when SKOV3 was treated
with 7.5 μg/ml clusterin for 48 hours (Figure W1).
Clusterin Expression Knockdown by siRNA Reduces
Paclitaxel Resistance of PEO4 Ovarian Cancer Cells
PEO4 is a paclitaxel-resistant cell line that expresses high levels of
clusterin. Clusterin protein levels were significantly lower both 24
and 48 hours after PEO4 cells were transfected with clusterin siRNA
(Figure 6A). No change in clusterin expression was observed in cells
transfected with the luciferase siRNA control. After 24 hours of
transfection with clusterin or luciferase siRNA, all PEO4 cells were
treated with 10−7 M paclitaxel for 48 hours. A correlation between
reduced clusterin expression and increased paclitaxel sensitivity was
observed (Figure 6B). Moreover, paclitaxel-induced apoptosis also
significantly increased when clusterin expression was knocked down
in PEO4 cells (Figure W2). Similar results were obtained in two
other paclitaxel-resistant cell lines, RMUG-S and TOV21G, which
express high levels of clusterin (Figure W3).
Figure 4. Increased paclitaxel resistance in clusterin transfectants.
(A) Western blot analysis showing overexpression of clusterin in
SKOV3 cells stably transfected with plasmid pcDNA3.1 with clus-
terin (cDNA3.1-Clu). (B) SKOV3-cDNA3.1-Clu stably transfected ex-
pressing clusterin had higher survival rates than the control cells
SKOV3-vector, which were transfected with pcDNA3.1 vector only.
Figure 3. Correlation of clusterin expression and paclitaxel resis-
tance. (A)Western blot analysis of clusterin expression in 13 epithe-
lial ovarian cancer cell lines. (B) Scatter plot showing correlation
between clusterin expression and paclitaxel IC50 for the 13 ovarian
cancer cell lines tested. High IC50 values denote paclitaxel resis-
tance, whereas low IC50 values indicate paclitaxel sensitivity. A
Spearman correlation test showed that clusterin overexpression
significantly correlated with IC50 for paclitaxel (R
2 = 0.55, P= .004).
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Clusterin Expression Knockdown in Ovarian Cancer Cells by
shRNA Reduces Tumor Size in Xenograft Mouse Models When
Treated with Paclitaxel
PEO4 cells transduced with Lentivirus carrying clusterin or LacZ
shRNA were xenografted into mice, and the effects of paclitaxel
were determined. After 22 days, the tumors that had developed
from the xenografted cells transduced with clusterin shRNA were
significantly smaller than those of the control groups (Figure 7A).
Decreased clusterin expression in xenografted tumor masses after
autopsy was confirmed by Western blot analysis and densitometer
quantification. The difference between shRNA-clusterin–treated tu-
mor and shRNA-control was significant (twofold decrease) with P =
.037 (Figure 7B).
Effect of Clusterin on Microtubule Binding
To evaluate whether clusterin confers paclitaxel resistance by pre-
venting the binding of paclitaxel to microtubules, both paclitaxel-
resistant PEO4 cells and paclitaxel-sensitive SKOV3 cells were treated
with identical concentrations of paclitaxel-OG. PEO4 cells had min-
imal microtubule staining in the absence or presence of exogenous
clusterin (Figure 8, A and B). In contrast, SKOV3 cells had strong
cytoplasmic staining in the absence of clusterin, whereas no stain-
ing was observed in the presence of exogenous clusterin, suggesting
that exogenous clusterin prevents the binding of paclitaxel to mi-
crotubules (Figure 8, C and D). To clarify the role of endogenous
clusterin, we infected PEO4 cells with Lentivirus carrying shRNA-
clusterin (Lenti-shRNA-clusterin) to knockdown the endogenous clus-
terin expression. The result showed that PEO4 cells infected with
Lenti-shRNA-clusterin had strong cytoplasmic stain by paclitaxel-
OG, whereas PEO4 cells infected with Lentivirus vector control
had undetectable staining similar to Figure 8, C and B, respectively
(Figure W4).
Figure 6. PEO4 became sensitive to paclitaxel after silencing clus-
terin expression with siRNA. (A) Western blot analyses show the
time course of clusterin silencing in PEO4 cells transfected with
siRNA for clusterin (+) or luciferase (−). After transfection, the
cells were cultured for 2 days in medium containing 10−7 M pac-
litaxel. (B) Cell survival after paclitaxel treatment as determined by
XTT assay.
Figure 7. Effects of decreased clusterin expression on paclitaxel
resistance in xenografted tumors. (A) When xenografts in nude
mice resulting from the inoculation of paclitaxel-resistant cells
transduced with shRNA for clusterin or the Lacz gene grew to ap-
proximately 100 mm3, mice were injected with 0.2 mg/0.1 ml per
10 g of paclitaxel intraperitoneally. Tumor volumes were measured
twice every week. (B) Western blot analysis of clusterin expression
from xenografted tumors from mouse autopsies. Tumors from
three separate mice from both the shRNA-Lacz and shRNA-clusterin
groups were analyzed.
Figure 5. Exogenous clusterin enhances the paclitaxel resistance of SKOV3 cells. Cell proliferation was measured by XTT assay in
SKOV3 cells treated with 10−7 M paclitaxel (T) for 48 hours in the presence of the indicated concentrations of clusterin. The baseline
used for calculating relative cell proliferation rate was set by adjusting the proliferation rate of paclitaxel-treated SKOV3 cells without
exogenous clusterin to 1.
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Binding Interactions between Clusterin and Paclitaxel
To evaluate whether clusterin binds specifically to paclitaxel, equi-
molar mixtures of clusterin or GST as a control and paclitaxel-OG,
phalloidin-OG, or OG were incubated together and then fraction-
ated by size exclusion chromatography. After incubation with clus-
terin, the elution profile of paclitaxel-OG adopted a pattern similar
to that of clusterin alone (Figure 9, A and B). In contrast, after in-
cubation with GST, the elution profile of paclitaxel-OG was similar
to that of paclitaxel-OG alone, implying that under these conditions,
the small molecule remained unbound. Similar results were obtained
with two other control proteins, superoxide dismutase and hemoglo-
bin (data not shown), and OG and phalloidin-OG, the control dyes
(Figure W5).
Discussion
By comparing the expression profiles generated from short- and
long-term ovarian cancer survivors, we found that clusterin expres-
sion was significantly higher in short- than in long-term survivors
(Figure 1). Also, Kaplan-Meier survival analyses of results from clus-
terin immunostaining in 62 samples of late-stage, high-grade ovarian
serous carcinomas indicated that the overexpression of clusterin cor-
relates with poor survival (Figure 2A). This is consistent with reports
that clusterin is a marker of poor prognosis in other cancer types [23–
27]. Moreover, overexpression of clusterin also correlates with che-
moresistance (Figure 2B).
Clusterin, also known as testosterone-repressed prostate message-2
(TRPM-2), sulfated glycoprotein-2 (SGP-2), SP-40, and apolipopro-
tein J (ApoJ), is a secreted heterodimeric glycoprotein encoded by a
single gene on chromosome 8p21-p12. When analyzed by SDS-
PAGE, clusterin migrates as a broad band at 70 to 80 kDa but
has an actual mass of approximately 61 kDa (determined by mass
spectrometry) [28]. Clusterin is present in various biologic fluids
[29] and has been implicated in several physiological processes, in-
cluding cell adhesion and aggregation [30], complement inhibition
[31], lipid transport, membrane protection, sperm maturation, and
endocrine secretion [31,32]. Clusterin expression has also been im-
plicated in chemoresistance in several other cancer types [14,15].
Because the resistance of tumor cells to various available chemother-
apeutic agents such as paclitaxel has been one of the major factors
leading to poor survival in ovarian cancer patients, we therefore hy-
pothesized that clusterin expression confers chemoresistance to ovar-
ian cancer cells.
In this study, we demonstrated that clusterin expression correlated
with paclitaxel resistance both in vitro and in vivo. We found that
high levels of clusterin expression in ovarian cancer cell lines corre-
lated with paclitaxel resistance, although a few cell lines with low
levels of clusterin expression were also resistant to paclitaxel (Fig-
ure 3). These cell lines might use mechanisms other than overexpres-
sion of clusterin to confer paclitaxel resistance such as the expression
of metabolizing enzyme cytochrome P450 or cellular efflux ABC
transporter [33]. To demonstrate the role of clusterin in paclitaxel re-
sistance, we manipulated the endogenous level of clusterin expression
in a paclitaxel-sensitive cell line (SKOV3, low level of endogenous
clusterin expression) and a paclitaxel-resistant cell line (PEO4, high
level of endogenous clusterin expression). We found that paclitaxel-
sensitive SKOV3 cells becamemore resistant to paclitaxel when endoge-
nous clusterin expression level was up-regulated (Figure 4). Conversely,
Figure 9. Coelution of clusterin and OG-labeled paclitaxel (paclitaxel-
OG) in size exclusion chromatography. Solutions containing clus-
terin and paclitaxel-OG mixture, paclitaxel-OG alone, or a GST and
paclitaxel-OG mixture (all at 5 mM) were fractionated by size exclu-
sion chromatography in PEM buffer, and the OG fluorescence and
A280 of the eluate were measured. The upper panel shows OG
fluorescence as a function of elution time; the lower panel shows
the corresponding A280 profile. The result shown is representative
of three independent experiments.
Figure 8. Exogenous clusterin prevents the binding of paclitaxel to
microtubules in SKOV3 cells. PEO4 (A and B) and SKOV3 (C and D)
cells cultured in chamber coverglasses were treated with 10−6 M
OG-labeled paclitaxel in the absence (A and C) or presence (B and
D) of 7.5 μg/ml clusterin for 30 minutes. Cells were also simulta-
neously incubated with the Hoechst stain for nuclei visualization,
and fluorescent images were captured by an inverted fluores-
cence microscope equipped with a digital camera using the same
setting. The binding of OG-labeled paclitaxel to microtubules is
shown in panel C.
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paclitaxel-resistant PEO4 cells became more sensitive to paclitaxel
and more apoptotic in vitro and in vivo when endogenous clusterin
expression level was down-regulated. These results indicated that high
levels of endogenous clusterin expression were involved in the pacli-
taxel resistance of ovarian cancer cells.
In addition to the endogenous clusterin, the exogenous clusterin
added in our experiments enhanced the paclitaxel resistance of
SKOV3 cells, as indicated by the cells’ increased survival rate and
the reduction in paclitaxel-induced apoptosis (Figure 5). The extent
of both the increased survival and the reduced apoptosis correlated
with the increase in concentration of exogenous clusterin. This sug-
gests that exogenous clusterin binds to extracellular paclitaxel and
subsequently prevents it from entering the cells and exerting toxicity.
To test the hypothesis that the exogenous clusterin secreted by ovar-
ian cancer cells inhibits the binding of paclitaxel to microtubules inside
the cells, we determined the level of microtubule-associated fluo-
rescence in paclitaxel-OG–treated ovarian cancer cells with or with-
out clusterin. Significant microtubule-associated fluorescence was
observed in SKOV3 cells (Figure 8C ) but not in PEO4 cells, which
expressed high levels of endogenous clusterin (Figure 8, A and B).
However, when SKOV3 cells were coincubated with both exogenous
clusterin and paclitaxel-OG, negligible microtubule-associated fluo-
rescence was observed (Figure 8D).
Using size exclusion chromatography to directly test whether clus-
terin bound specifically to paclitaxel in solution, we found that
clusterin did bind to paclitaxel-OG but not to phalloidin-OG or
OG alone and that GST and other control proteins did not bind
to paclitaxel-OG. In addition, ELISA confirmed that clusterin bound
with high affinity to paclitaxel but not at all to other therapeutic
agents, such as cisplatin and carboplatin (data not shown). This is
the first time we are aware of that the binding of clusterin and pac-
litaxel has been clearly demonstrated, although clusterin’s role in che-
moresistance has been suggested by previous reports in other cancer
types [14–16]. Thus, our results suggest that clusterin, which is gen-
erally a secreted molecule, may protect cancer cells from paclitaxel
toxicity by binding to the agent in the extracellular microenviron-
ment and preventing it from entering the cell to exert its toxic effects.
In conclusion, clusterin overexpression significantly correlates with
decreased survival in ovarian cancer patients, and clusterin confers re-
sistance to paclitaxel-induced apoptosis in ovarian cancer cells. The
mechanism of resistance may involve clusterin (potentially in both
extra- and intracellular locations) complexing with paclitaxel to inac-
tivate the agent’s cytotoxic activity. Therefore, targeting the reduction
of clusterin expression may be a worthwhile new therapeutic modality
for treating ovarian tumors expressing high levels of clusterin.
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Table W1. List of Genes Up-regulated in Short-term Survivors.
ProbeSet ID Gene Name Fold Change q (%)
205051_s_at v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 4.2 0
207480_s_at Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse) 3.3 0
226977_at similar to bovine IgA regulatory protein 3.7 4.5
230000_at chromosome 17 open reading frame 27 3.1 4.5
212327_at hypothetical protein 3.5 11.6
200795_at SPARC-like 1 (mast9, hevin) 3.4 11.6
204115_at guanine nucleotide binding protein (G protein), gamma 11 3.4 11.6
227354_at phosphoprotein associated with glycosphingolipid microdomains 1 3.3 11.6
209348_s_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) 3.3 11.6
210346_s_at CDC-like kinase 4 3.2 11.6
227131_at mitogen-activated protein kinase kinase kinase 3 3 11.6
206595_at cystatin E/M 5.2 11.7
223204_at chromosome 4 open reading frame 18 4.4 11.7
238067_at TBC1 domain family, member 8B (with GRAM domain) 4.2 11.7
220940_at KIAA1641 4.2 11.7
213905_x_at biglycan /// teashirt family zinc finger 1 4.1 11.7
211458_s_at GABA(A) receptor–associated protein like 1 /// GABA(A) receptors
associated protein like 3
4 11.7
1559060_a_at KIAA1961 gene 4 11.7
228256_s_at erythrocyte membrane protein band 4.1 like 4A 4 11.7
204777_s_at mal, T-cell differentiation protein 4 11.7
1559360_at Ephrin-A5 3.9 11.7
208791_at clusterin 3.8 11.7
208792_s_at clusterin 3.8 11.7
201261_x_at biglycan 3.8 11.7
233952_s_at zinc finger protein 295 3.7 11.7
241893_at Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N
acetyl-glucosaminyltransferase
3.6 11.7
214705_at InaD-like (Drosophila) 3.6 11.7
225990_at Boc homolog (mouse) 3.6 11.7
202733_at procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase),
alpha polypeptide II
3.6 11.7
229285_at ribonuclease L (2′,5′-oligoisoadenylate synthetase–dependent) 3.5 11.7
214246_x_at misshapen-like kinase 1 (zebrafish) 3.4 11.7
224831_at cytoplasmic polyadenylation element binding protein 4 3.3 11.7
223681_s_at InaD-like (Drosophila) 3.3 11.7
225688_s_at pleckstrin homology-like domain, family B, member 2 3.2 11.7
222154_s_at DNA polymerase-transactivated protein 6 3.1 11.7
202430_s_at phospholipid scramblase 1 3.1 11.7
202007_at nidogen 1 3.1 11.7
218656_s_at lipoma HMGIC fusion partner 3.1 11.7
218353_at regulator of G-protein signaling 5 3 11.7
229795_at Transcribed locus 3 11.7
201865_x_at nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 3 11.7
236313_at cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 3 11.7
225275_at EGF-like repeats and discoidin I–like domains 3 7 14.3
37170_at BMP2 inducible kinase 5.8 14.3
229831_at contactin 3 (plasmacytoma-associated) 4.8 14.3
230869_at Transcribed locus, moderately similar to NP_775622.1 transmembrane
protein 28 [Mus musculus]
4.6 14.3
211675_s_at MyoD family inhibitor domain containing /// MyoD family inhibitor
domain containing
4.4 14.3
201438_at collagen, type VI, alpha 3 4.3 14.3
212764_at — 4.2 14.3
230865_at Lix1 homolog (mouse) 4 14.3
228067_at similar to 2010300C02Rik protein 3.9 14.3
223343_at membrane-spanning 4-domains, subfamily A, member 7 3.8 14.3
224724_at sulfatase 2 3.8 14.3
206167_s_at Rho GTPase activating protein 6 3.8 14.3
212328_at hypothetical protein 3.8 14.3
237001_at NIK and IKK{beta} binding protein 3.7 14.3
221538_s_at plexin A1 3.5 14.3
212240_s_at phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) 3.5 14.3
230069_at sideroflexin 1 3.5 14.3
212980_at ubiquitin-specific peptidase 34 3.5 14.3
204872_at transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) 3.5 14.3
212586_at calpastatin 3.4 14.3
236241_at Mediator of RNA polymerase II transcription, subunit 31 homolog
(Saccharomyces cerevisiae)
3.4 14.3
227955_s_at CDNA: FLJ22256 fis, clone HRC02860 3.3 14.3
201185_at HtrA serine peptidase 1 3.3 14.3
206101_at extracellular matrix protein 2, female organ and adipocyte-specific 3.3 14.3
231853_at tubulin, delta 1 3.2 14.3
Table W1. (continued )
ProbeSet ID Gene Name Fold Change q (%)
223843_at scavenger receptor class A, member 3 3.2 14.3
219489_s_at nucleoredoxin 3.1 14.3
212757_s_at calcium/calmodulin–dependent protein kinase (CaM kinase) II gamma 3.1 14.3
202878_s_at CD93 molecule 3.1 14.3
235085_at homolog of rat pragma of Rnd2 3.1 14.3
224565_at trophoblast-derived noncoding RNA 3.1 14.3
202086_at myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) 3.1 14.3
219777_at GTPase, IMAP family member 6 3 14.3
224837_at forkhead box P1 3 14.3
224694_at anthrax toxin receptor 1 3 14.3
Figure W1. Two ovarian cancer cell lines, OVCA432 and SKOV3 were treated with 7.5 μg/ml clusterin for 48 hours. Cell proliferation was
measured with XTT assay.
Figure W2. Relative ratio of paclitaxel-induced DNA fragmentation
in PEO4 cells transfected with luciferase siRNA or clusterin siRNA.
DNA fragmentation, as assayed by quantitative cell death detec-
tion ELISA, indicated the extent of apoptosis. Values displayed
are the mean of three experiments, each conducted with quadru-
plicated samples.
Figure W3. siRNA knockdown experiments on three additional
ovarian cancer cell lines. Cells were transduced with Lentiviral vec-
tors with siRNA for luciferase and clusterin. Western blot analysis
(upper panel) was used to confirm clusterin silencing in two ovar-
ian cancer cell lines with high levels of clusterin expression. Treat-
ment with paclitaxel (T) decreased the relative cell proliferation,
i.e., the number of viable clusterin siRNA-transfected cells, signif-
icantly more than it decreased the number of Luciferase siRNA-
transfected cells (lower panel).
Figure W4. Cytoplasmic staining of OG-labeled paclitaxel in PEO4
cells after clusterin expression was silenced by Lentivirus carrying
shRNA-clusterin. PEO4 cells were infected with Lentivirus with
shRNA-clusterin (A) or vector control (B) for 48 hours in chamber
slides. Subsequently, cells were treated with 10−6 M OG-labeled
paclitaxel for 2 hours. Cells were counterstained with DAPI for nu-
clei and fluorescent images were captured.
Figure W5. Solutions containing clusterin and either OG or phalloidin-OG (all at 5 μM) were fractionated by size exclusion chromatography
in PEM buffer, and the OG fluorescence and A280 of the eluate were measured as described in the Materials and Methods section. The
upper panel shows OG fluorescence as a function of elution time; the lower panel shows the corresponding A280 profile. The identity of
individual traces is indicated in the corresponding key.
